Taken together these data suggest BMP9 as a possible therapeutic target in prostate cancer and provide a new rationale for ongoing clinical development of drugs blocking BMP9 signaling via ALK1 and ALK2. This evidence concerns the gene ACVR1 and prostate carcinoma.